Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.07 -0.26 (-0.64%) Market Cap: 4.86 Bil Enterprise Value: 4.65 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 38/100

Apellis Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) - Fireside Chat Transcript

Sep 10, 2020 / 07:20PM GMT
Release Date Price: $29.44 (-1.93%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Okay. It looks like it's working well. Great. So welcome, everyone, to the Apellis fireside chat. I have Cedric Francois, CEO; and Tim Sullivan, CFO; and Adam Townsend, Head of Commercial. So welcome to all of you. And I think everyone knows me. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. (Operator Instructions)

So with that, welcome, gentlemen. Thank you so much for participating in the panel.

Cedric, I think maybe just to start off, it would be great if you could just do a quick 3-, 4-minute intro just to help everyone get up to speed on what Apellis does, what is the mission of the company and what are the key milestones to expect coming up?

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you so much, Yigal. And thank you again for hosting us at this year's conference, different from last year, but very special nonetheless.

So for those of you not familiar with Apellis, we are a company focused on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot